New drug combo shows promise for Hard-to-Treat breast cancer

NCT ID NCT03568422

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CFI-402257 combined with the standard chemotherapy paclitaxel in people with advanced HER2-negative breast cancer that cannot be cured. The goal is to see if the combination works better than paclitaxel alone at slowing tumor growth. About 37 women will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

BCCA - Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.